Navigation Links
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
Date:9/5/2008

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases. Sunesis and SARcode entered into a license agreement providing SARcode with an exclusive license to Sunesis' LFA-1 technology to develop LFA-1 inhibitors in March 2006.

"LFA-1 antagonists mediate both migration and adhesion of the white blood cells to sites of inflammation as part of the body's immune response," said Tom Gadek, Ph.D., chief executive officer of SARcode Corporation. "Lead indications for LFA-1 include dry eye and allergic conjunctivitis, both large indications with unmet medical needs. The results of this study will inform dose selection for several Phase 2 studies to commence in the first half of 2009."

"We congratulate SARcode on the progress they have made moving this program forward into the clinic," said Daniel Swisher, chief executive officer and president of Sunesis. "The LFA-1 inhibitor product candidate, which was discovered at Sunesis, has the potential to address immunological and inflammatory diseases, including dry eye syndrome. We look forward to SARcode's continued advancement of this novel compound."

As part of the license agreement, Sunesis has earned a milestone payment from SARcode of $500,000 and a $375,000 convertible note. The next payable milestone, if earned, will be for initiation of the Phase 2 clinical program.

About SARcode

SARcode is a privately-held biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/ anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases.

About Sunesis Pharmaceuticals <
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
2. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
10. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the second ... "The second quarter of 2014 ... Doug Murphy-Chutorian , M.D., chief executive officer of ...
(Date:7/25/2014)... N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... clinic, GPM Pediatrics, reacts to a recent study, which ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... exposed to severe stress are more likely than others to ... months before pregnancy." There were two specific types ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
(Date:7/26/2014)... According to the "Get Rid Tattoo Naturally" book ... guide that provides readers with safe and natural methods ... teaches them how to fade dark colored tattoos, and ... home for drastic results. , Vkool reveals in ... step-by-step tutorials and product recommendations for treating different ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 PersonalInjurySolicitorsIreland, ... legal help to people who have suffered from ... launch of both their new company, and a ... on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , ... The focus of the company is always on ...
(Date:7/25/2014)... According to a new market research ... monitoring, thermography, ultrasound emission, lubricating oil analysis, corrosion ... Geography - Global Forecast to 2014 - 2020", ... is expected to reach $2.50 at a CAGR ... 117 market data Tables and 57 Figures spread ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... America (GSA) the nation,s largest interdisciplinary ... has chosen Heather M. Young, PhD, RN, FAAN, ... 2014 recipient of the Doris Schwartz Gerontological Nursing ... GSA,s Health Sciences Section, is given to a ... and sustained contribution to gerontological nursing research. , ...
Breaking Medicine News(10 mins):Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... Brigid Waldron-Perrine, Ph.D., a recent graduate from Wayne State University, ... at Wayne State University,s College of Liberal Arts and Sciences, ... to a higher power, it can help them rehabilitate. The ... Traumatic brain injury is a disruption of normal brain ...
... -- New mandatory safety standards for cribs in the United ... ensuring a safe environment for infants as they sleep," according ... and Human Development. Under the new Consumer Product Safety ... cribs will be banned, mattress supports will be stronger, crib ...
... LINDA, Calif. Health disparities between black Americans and ... medical journals. But one study shows that blacks who ... report a better quality of life than the average ... possible explanation for the difference. The research was conducted ...
... has confirmed that between 10-20% of breast cancers classified ... when and why breast cancers may be misclassified has ... with breast cancer. Its findings are published online in ... A woman diagnosed with breast cancer can be ...
... June 27, 2011 In today,s society where access to ... appropriate media usage for their children and how media consumption ... Dimitri A. Christakis, MD, MPH and Dr. Michelle M. Garrison, ... of media and assess how media usage can lead to ...
... NEW YORK (June 27, 2011) -- As required under the ... people will soon be added to the ranks of the ... a different, potentially problematic trend that could end up hampering ... accepting fewer and fewer patients with health insurance, according to ...
Cached Medicine News:Health News:Religion benefits traumatic brain injury victims, Wayne State University research finds 2Health News:New Crib Safety Rules to Take Effect 2Health News:Black members of Adventist church defy health disparities, study shows 2Health News:Studies examine impact of media use among youth, recommend preventative measures 2Health News:Studies examine impact of media use among youth, recommend preventative measures 3Health News:Surprising drop in physicians' willingness to accept patients with insurance 2
... long-standing tradition of the original Hoffmann® ... today's surgeon with advanced technology and ... loaded snap fit mechanism allows the ... rods or pins providing versatile intraoperative ...
... OMNIPAQUE is an X-ray contrast ... and children for: angiography, urography, ... computed tomography of the basal ... endoscopic retrograde cholangio (pancreato) graphy ...
... contrast agent FDA-approved for administration by power ... IV contrast media for MR imaging of ... has convenient packaging options for just the ... problem-free delivery. You can trust OptiMARK ...
... was launched in the U.S. in 1993 ... nervous system (CNS) to detect lesions of ... OMNISCAN has since received approval for adult ... CNS and body indications. OMNISCAN comes in ...
Medicine Products: